The Filings Report

Cigna Group

CINYSECIK 1739940Healthcare / Healthcare Plansfiscal year ends December38 quarters since 2017

Revenue, Q2 FY2026
$71.7B
+6.7% on Q2 FY2025
Net income
$1.7B
+8.4% on Q2 FY2025
Free cash flow
—
no year-earlier figure
Diluted EPS
$6.29
+10.2% on Q2 FY2025
Revenue, TTM
$282.4B
trailing four quarters
Net margin, TTM
2.3%
net income $6.4B
Free cash flow, TTM
—
Cash and equivalents
$6.3B
long-term debt —, Jun 30, 2026
Shares, 12-month change
−1.0%
264M shares, Jun 30, 2026
Buybacks, TTM
$1.3B
1.6% of market value
Dividends, TTM
$1.6B
2.1% of market value
Market value
$78.8B
at the close, buybacks

Latest quarter Q2 FY2026, filed July 30, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Cigna Group reported revenue of $71.7B, +6.7% on Q2 FY2025, and net income of $1.7B (+8.4%). Operating margin was 3.7%. Diluted earnings per share were $6.29.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of July 30, 2026.

Revenue and net incomeRevenueNet income
−$20B$0$20B$40B$60B$80BQ3'22, Revenue: $45.3BQ3'22, Net income: $2.8BQ3'22Q4'22, Revenue: $45.8BQ4'22, Net income: $1.2BQ4'22Q1'23, Revenue: $46.5BQ1'23, Net income: $1.3BQ1'23Q2'23, Revenue: $48.6BQ2'23, Net income: $1.5BQ2'23Q3'23, Revenue: $49.0BQ3'23, Net income: $1.4BQ3'23Q4'23, Revenue: $51.1BQ4'23, Net income: $1.0BQ4'23Q1'24, Revenue: $57.3BQ1'24, Net income: −$277MQ1'24Q2'24, Revenue: $60.5BQ2'24, Net income: $1.5BQ2'24Q3'24, Revenue: $63.7BQ3'24, Net income: $739MQ3'24Q4'24, Revenue: $65.6BQ4'24, Net income: $1.4BQ4'24Q1'25, Revenue: $65.5BQ1'25, Net income: $1.3BQ1'25Q2'25, Revenue: $67.2BQ2'25, Net income: $1.5BQ2'25Q3'25, Revenue: $69.7BQ3'25, Net income: $1.9BQ3'25Q4'25, Revenue: $72.5BQ4'25, Net income: $1.2BQ4'25Q1'26, Revenue: $68.5BQ1'26, Net income: $1.7BQ1'26Q2'26, Revenue: $71.7BQ2'26, Net income: $1.7BQ2'26−$20B$0$20B$40B$60B$80BQ3'22, Revenue: $45.3BQ3'22, Net income: $2.8BQ4'22, Revenue: $45.8BQ4'22, Net income: $1.2BQ4'22Q1'23, Revenue: $46.5BQ1'23, Net income: $1.3BQ2'23, Revenue: $48.6BQ2'23, Net income: $1.5BQ2'23Q3'23, Revenue: $49.0BQ3'23, Net income: $1.4BQ4'23, Revenue: $51.1BQ4'23, Net income: $1.0BQ4'23Q1'24, Revenue: $57.3BQ1'24, Net income: −$277MQ2'24, Revenue: $60.5BQ2'24, Net income: $1.5BQ2'24Q3'24, Revenue: $63.7BQ3'24, Net income: $739MQ4'24, Revenue: $65.6BQ4'24, Net income: $1.4BQ4'24Q1'25, Revenue: $65.5BQ1'25, Net income: $1.3BQ2'25, Revenue: $67.2BQ2'25, Net income: $1.5BQ2'25Q3'25, Revenue: $69.7BQ3'25, Net income: $1.9BQ4'25, Revenue: $72.5BQ4'25, Net income: $1.2BQ4'25Q1'26, Revenue: $68.5BQ1'26, Net income: $1.7BQ2'26, Revenue: $71.7BQ2'26, Net income: $1.7BQ2'26

Net income losses drawn in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$3B$5B$8B$10BQ3'22, Cash and equivalents: $7.1BQ3'22Q4'22, Cash and equivalents: $5.9BQ4'22Q1'23, Cash and equivalents: $7.9BQ1'23Q2'23, Cash and equivalents: $9.6BQ2'23Q3'23, Cash and equivalents: $8.5BQ3'23Q4'23, Cash and equivalents: $7.8BQ4'23Q1'24, Cash and equivalents: $8.4BQ1'24Q2'24, Cash and equivalents: $6.8BQ2'24Q3'24, Cash and equivalents: $5.9BQ3'24Q4'24, Cash and equivalents: $7.5BQ4'24Q1'25, Cash and equivalents: $8.3BQ1'25Q2'25, Cash and equivalents: $4.3BQ2'25Q3'25, Cash and equivalents: $6.0BQ3'25Q4'25, Cash and equivalents: $7.7BQ4'25Q1'26, Cash and equivalents: $7.0BQ1'26Q2'26, Cash and equivalents: $6.3BQ2'26$0$3B$5B$8B$10BQ3'22, Cash and equivalents: $7.1BQ4'22, Cash and equivalents: $5.9BQ4'22Q1'23, Cash and equivalents: $7.9BQ2'23, Cash and equivalents: $9.6BQ2'23Q3'23, Cash and equivalents: $8.5BQ4'23, Cash and equivalents: $7.8BQ4'23Q1'24, Cash and equivalents: $8.4BQ2'24, Cash and equivalents: $6.8BQ2'24Q3'24, Cash and equivalents: $5.9BQ4'24, Cash and equivalents: $7.5BQ4'24Q1'25, Cash and equivalents: $8.3BQ2'25, Cash and equivalents: $4.3BQ2'25Q3'25, Cash and equivalents: $6.0BQ4'25, Cash and equivalents: $7.7BQ4'25Q1'26, Cash and equivalents: $7.0BQ2'26, Cash and equivalents: $6.3BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Cigna Group income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue71,66868,49472,47269,74867,17865,50265,64963,694+6.7%
Cost of revenue56,70354,10057,79555,53053,26848,39849,02147,565+6.4%
Gross profit—————————
Research and development—————————
Selling, general and administrative3,4703,7223,6093,3623,4334,2133,8653,590+1.1%
Operating income2,6762,3582,3452,5782,3061,9712,1732,576+16.0%
Other income (expense)(356)(357)(362)(347)(337)(362)(362)(376)−5.6%
Pretax income2,2572,2701,8172,2952,0211,6482,0091,192+11.7%
Income tax382409543322389239473367−1.8%
Net income1,6601,6541,2341,8681,5321,3231,424739+8.4%
Diluted EPS ($)6.296.26—6.985.714.85—2.63+10.2%
Diluted shares (millions)264264—268268273—281—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Cigna Group balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents6,2987,0407,6766,0254,3298,3347,5505,888+45.5%
Short-term investments9598121,056883813727665864+18.0%
Total current assets46,99143,03247,81446,73544,72343,55548,87049,222+5.1%
Total assets157,082153,266157,919157,919151,651150,658155,881157,639+3.6%
Total current liabilities55,56252,60656,34256,45356,77955,74557,97957,060−2.1%
Long-term debt—————————
Total liabilities114,172110,824116,045115,905111,221110,244114,638115,341+2.7%
Stockholders’ equity42,62042,21041,71341,80540,21440,22641,03342,095+6.0%
Shares outstanding (millions)264265264267267267274278—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Cigna Group cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow(421)1,1316,1493,418(1,886)1,9205,21246+77.7%
Capital expenditures—————————
Free cash flow (CFO − capex)—————————
Depreciation and amortization655650722697682674646650−4.0%
Share repurchases28001,00101,1121,5082,0220−74.8%
Dividends paid409417396402401412384390+2.0%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

Cigna Group income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 29, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 28, 2019FY2016ended Dec 31, 2016filed Feb 28, 2019
Revenue274,900247,121195,265180,518174,069160,401153,56648,65041,80639,838
Cost of revenue214,991182,509133,801124,834117,553103,48497,6684,7932,4562,468
Gross profit——————————
Research and development——————————
Selling, general and administrative14,61714,84414,82213,17413,01214,07214,05311,93410,0309,790
Operating income9,2009,4178,5368,4507,9418,1538,0774,1603,9423,088
Other income (expense)(1,408)(1,435)(1,446)(1,228)(1,208)(1,438)(1,682)(498)(252)(278)
Pretax income7,7815,2695,5138,3976,79010,8686,5703,5813,6062,979
Income tax1,4931,4911411,6151,3702,3791,4509351,3741,136
Net income5,9573,4345,1646,7045,3708,4585,1042,6372,2371,867
Diluted EPS ($)22.1812.1217.3921.4115.7522.9613.4410.548.777.19
Diluted shares (millions)269283297313341368380250255260

Balance sheet

Cigna Group balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 29, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 28, 2019FY2016ended Dec 31, 2016filed Feb 28, 2019
Cash and equivalents7,6767,5507,8225,9245,08110,1824,6193,8552,9723,185
Short-term investments1,0566659259059201,3319372,0452,136—
Total current assets47,81448,87037,35130,12236,13427,79929,84520,4309,311—
Total assets157,919155,881152,761143,885154,889155,451155,774153,22661,759—
Total current liabilities56,34257,97948,71641,22543,57236,02240,13831,89511,009—
Long-term debt———————39,523——
Total liabilities116,045114,638106,41099,131107,705105,065110,395112,15447,999—
Stockholders’ equity41,71341,03346,22344,67547,11250,32145,33841,02813,711—
Shares outstanding (millions)264274292297321352372380——

Cash flow statement

Cigna Group cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 29, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 28, 2019FY2016ended Dec 31, 2016filed Feb 28, 2019
Operating cash flow9,60110,36311,8138,6567,19110,3509,4853,7704,0864,026
Capital expenditures——————1,050528471461
Free cash flow (CFO − capex)——————8,4353,2423,6153,565
Depreciation and amortization2,7752,7753,0352,9372,9232,8023,651695566610
Share repurchases3,6217,0342,2847,6077,7424,0421,9873422,725139
Dividends paid1,6111,5671,4501,3841,3411515———

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$6M
3 sales by 2 insiders; officers and directors $6M
Bought, twelve months
$1000K
1 purchases by 1 insider; officers and directors $1000K
Sold, twelve months
$67M
19 sales by 4 insiders; officers and directors $67M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 3, 2026Neville EverettSee Remarksopen-market sale10b5-1617$284.05$175K5,053Sep 8, 2026
Sep 1, 2026Evanko Brian CSee Remarksaward3,113$0.00—41,030Sep 3, 2026
Aug 18, 2026Jones Nicole SSee Remarksopen-market sale10b5-12,677$279.61$749K25,880Aug 20, 2026
Aug 5, 2026Jones Nicole SSee Remarksoption exercise1,301$192.02$250K28,557Aug 6, 2026
Aug 4, 2026Jones Nicole SSee Remarksoption exercise14,045$192.02$3M46,692Aug 6, 2026
Aug 4, 2026Jones Nicole SSee Remarksopen-market sale10b5-119,436$276.27$5M27,256Aug 6, 2026
Jun 12, 2026Kates Jamie GChief Accounting Officeroption exercise899$152.89$137K3,267Jun 16, 2026
Jun 12, 2026Kates Jamie GChief Accounting Officeropen-market sale899$298.61$268K2,368Jun 16, 2026
Jun 1, 2026Koka Durga PrasadEVP, Global CIOtax withholding729$275.53$201K6,552Jun 3, 2026
May 13, 2026Cordani DavidChairman & CEO, Directoroption exercise15,458$149.13$2M49,795May 14, 2026
May 13, 2026Cordani DavidChairman & CEO, Directoroption exercise7,971$197.35$2M57,766May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoroption exercise103,595$149.13$15M150,696May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoroption exercise85,519$197.35$17M236,215May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-13,903$286.83$1M232,312May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-114,292$287.96$4M218,020May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-113,839$288.85$4M204,181May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-141,099$290.00$12M163,082May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-113,732$291.01$4M149,350May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-112,315$291.95$4M137,035May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-17,861$292.88$2M129,174May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-12,142$293.92$630K127,032May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-138,487$294.98$11M88,545May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-134,641$295.98$10M53,904May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-12,017$296.84$599K51,887May 14, 2026
May 12, 2026Cordani DavidChairman & CEO, Directoropen-market sale10b5-115,319$298.24$5M36,568May 14, 2026

Full insider history for Cigna Group, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held CI in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded CI by quarter.

FundManagerQuarterValueSharesWeightMove
Greenlight CapitalDavid EinhornQ2 2026$24M88,4000.62%held

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
The Cigna Group, CIK 1739940 on EDGAR
Extract generated
August 27, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2023
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss, NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/CI.json